Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension.
Official registry: https://clinicaltrials.gov/study/NCT03312556 · Vanderbilt University Medical Center · enrollment listed as 12
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are continuous positive airway pressure (CPAP), or Placebo. The registry lists allocation as randomized. Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure.
They plan to enroll about 12 people at Nashville. Taking part typically means taking a study drug (or dummy pill), using or being fitted with a device plus check-ins.
Treatment of Supine Hypertension in Autonomic Failure With Continuous Positive Airway Pressure
Interventions: continuous positive airway pressure (CPAP), Placebo
Primary outcome (registry wording): Supine Systolic Blood Pressure
Bonnie K Black, RN
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
This study is not a treatment protocol and no experimental treatments are involved. Study participants may be seen as needed for clinical, translational and basic research studies, or as medically indicated.
NCT00081523 · Official ClinicalTrials.gov record · National Heart, Lung, and Blood Institute (NHLBI)
Background: \- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause.
NCT01730092 · Official ClinicalTrials.gov record · National Institutes of Health Clinical Center (CC)
Background: \- Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs.
NCT02417740 · Official ClinicalTrials.gov record · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary